Marksans Pharma Balance Sheet Annual

Trade

BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026 | Sector: Biotechnology & Drugs

315.70 +7.15 (2.32%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Cash Equivalents	673.58	294.91	49.72	-
Short Term Investments	33.90	332.65	140.29	157.78
Cashand Short Term Investments	707.47	715.08	346.69	209.38
Accounts Receivable- Trade Net	453.18	416.85	394.78	271.38
Total Receivables Net	458.10	419.48	397.83	271.38
Total Inventory	617.94	484.74	424.44	404.32
Other Current Assets Total	78.98	36.19	32.23	17.17
Total Current Assets	1,862.49	1,675.30	1,201.20	902.25
Property/ Plant/ Equipment Total- Net	681.09	386.89	342.29	254.02
Goodwill Net	39.50	38.49	30.03	19.59
Intangibles Net	64.76	70.80	58.57	47.44
Note Receivable- Long Term	3.73	4.35	2.61	2.56
Other Long Term Assets Total	29.38	14.57	5.41	2.39
Total Assets	2,680.95	2,190.39	1,640.10	1,228.25
Accounts Payable	268.28	230.60	200.08	168.66
Notes Payable/ Short Term Debt	29.09	41.59	41.29	18.74
Current Portof LT Debt/ Capital Leases	24.95	15.67	28.05	6.04
Other Currentliabilities Total	67.53	42.69	75.83	96.11
Total Current Liabilities	389.85	340.99	356.22	298.40
Capital Lease Obligations	190.02	65.69	41.43	9.33
Total Long Term Debt	190.02	65.69	41.43	14.33
Total Debt	244.06	122.95	110.78	39.10
Deferred Income Tax	10.62	15.39	17.62	8.06
Minority Interest	20.85	19.91	20.70	18.86
Other Liabilities Total	4.56	3.25	1.86	2.11
Total Liabilities	615.90	445.23	437.83	341.76
Common Stock Total	45.32	45.32	40.93	40.93
Retained Earnings( Accumulated Deficit)	2,019.74	1,105.50	924.66	657.17
Total Equity	2,065.05	1,745.16	1,202.27	886.49
Total Liabilities Shareholders' Equity	2,680.95	2,190.39	1,640.10	1,228.25
Total Common Shares Outstanding	45.32	45.32	40.93	40.93
Tangible Book Valueper Share Common Eq	43.27	36.10	27.21	20.02
Cash	-	87.52	156.69	51.60
Prepaid Expenses	-	19.80	-	-
Property/ Plant/ Equipment Total- Gross	-	623.18	546.70	410.43
Accumulated Depreciation Total	-	-236.29	-204.41	-156.40
Accrued Expenses	-	10.44	10.97	8.85
Additional Paid- In Capital	-	504.50	173.19	175.13
Other Equity Total	-	89.85	63.49	13.26
Long Term Debt	-	-	-	5.00